CALC
CalciMedica, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
CalciMedica, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
CalciMedica, Inc.
1.35
−0.12 · −8.16%
post 1.35 0.00%
No changes.
No changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for CalciMedica, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for CalciMedica, Inc..
Annual filing, covered
10-K parsed · Mar 3 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 3 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC, Graybug Vision, Inc. in 2016 and changed its name to CalciMedica, Inc. in 2023. CalciMedica, Inc. was incorporated in 2011 and is based in Redwood City, California.
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC, Graybug Vision, Inc. in 2016 and changed its name to CalciMedica, Inc. in 2023. CalciMedica, Inc. was incorporated in 2011 and is based in Redwood City, California.
| Manager | Value | % base | |
|---|---|---|---|
| Woodline Partners | $2.6M | 25.37% | new |
| Stonepine | $2.2M | 21.68% | new |
| Heights | $1.6M | 15.85% | new |
| Squadron | $1.3M | 12.68% | new |
| StemPoint Capital | $1.2M | 11.83% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Woodline Partners | $2.6M | 25.37% | new |
| Stonepine | $2.2M | 21.68% | new |
| Heights | $1.6M | 15.85% | new |
| Squadron | $1.3M | 12.68% | new |
| StemPoint Capital | $1.2M | 11.83% | new |
Expected move
No implied move.
Bull1
Bear2